{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:40:28Z","timestamp":1790480428551,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the effects of daily adaptive MR-guided replanning in stereotactic body radiation therapy (SBRT) of liver metastases based on a patient individual longitudinal dosimetric analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifteen patients assigned to SBRT for oligometastatic liver metastases underwent daily MR-guided target localization and on-table treatment plan re-optimization. Gross tumor volume (GTV) and organs at risk (OARs) were adapted to the anatomy-of-the-day. A reoptimized plan (RP) and a rigidly shifted baseline plan (sBP) without re-optimization were generated for each fraction. After extraction of DVH parameters for GTV, planning target volume (PTV), and OARs (stomach, duodenum, bowel, liver, heart) plans were compared on a per-patient basis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median pre-treatment GTV and PTV were 14.9\u00a0cc (interquartile range (IQR): 7.7\u201332.9) and 62.7\u00a0cc (IQR: 42.4\u2013105.5) respectively. SBRT with RP improved PTV coverage (V100%) for 47\/75 of the fractions and reduced doses to the most proximal OARs (D1cc, Dmean) in 33\/75 fractions compared to sBP. RP significantly improved PTV coverage (V100%) for metastases within close proximity to an OAR by 4.0% (\u2264\u20090.2\u00a0cm distance from the edge of the PTV to the edge of the OAR; n\u2009=\u20097; <jats:italic>p<\/jats:italic>\u2009=\u20090.01), but only by 0.2% for metastases farther away from OAR (&gt;\u20092\u00a0cm distance; n\u2009=\u20097; <jats:italic>p<\/jats:italic>\u2009=\u20090.37). No acute grade 3 treatment-related toxicities were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MR-guided online replanning SBRT improved target coverage and OAR sparing for liver metastases with a distance from the edge of the PTV to the nearest luminal OAR\u2009&lt;\u20092\u00a0cm. Only marginal improvements in target coverage were observed for target distant to critical OARs, indicating that these patients do not benefit from daily adaptive replanning.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01813-6","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T13:03:57Z","timestamp":1620133437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis"],"prefix":"10.1186","volume":"16","author":[{"given":"Michael","family":"Mayinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian M.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Dal Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"Weitkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matea","family":"Pavic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Garcia Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Unkelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tanadini-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"10185","key":"1813_CR1","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"18","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;18(10185):2051\u20138. 393.","journal-title":"Lancet"},{"issue":"6","key":"1813_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","volume":"16","author":"JY Chang","year":"2015","unstructured":"Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630\u20137.","journal-title":"Lancet Oncol"},{"key":"1813_CR3","doi-asserted-by":"crossref","unstructured":"Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572\u20138.","DOI":"10.1200\/JCO.2008.19.6329"},{"key":"1813_CR4","doi-asserted-by":"crossref","unstructured":"Andratschke N, Alheid H, Allg\u00e4uer M, Becker G, Blanck O, Boda-Heggemann J, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18(1):283.","DOI":"10.1186\/s12885-018-4191-2"},{"issue":"7","key":"1813_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1080\/02841860600904821","volume":"45","author":"J Wulf","year":"2006","unstructured":"Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45(7):838\u201347.","journal-title":"Acta Oncol"},{"key":"1813_CR6","doi-asserted-by":"crossref","unstructured":"Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128\u201337.","DOI":"10.1002\/cncr.29161"},{"key":"1813_CR7","doi-asserted-by":"crossref","unstructured":"Crane CH. Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. J Radiat Res. 2016;57Suppl 1:i53\u20137.","DOI":"10.1093\/jrr\/rrw016"},{"key":"1813_CR8","doi-asserted-by":"crossref","unstructured":"Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623\u201331.","DOI":"10.1002\/cncr.20539"},{"issue":"9","key":"1813_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1097\/JTO.0b013e318260e00d","volume":"7","author":"IS Grills","year":"2012","unstructured":"Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol. 2012;7(9):1382\u201393.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1813_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement RJ, Guckenberger M, Alheid H, Allg\u00e4uer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123(2):227\u201333.","journal-title":"Radiother Oncol"},{"key":"1813_CR11","doi-asserted-by":"crossref","unstructured":"Liu F, Erickson B, Peng C, Li XA. Characterization and management of interfractional anatomic changes for pancreatic cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(3):e423\u20139.","DOI":"10.1016\/j.ijrobp.2011.12.073"},{"key":"1813_CR12","doi-asserted-by":"crossref","unstructured":"Acharya S, Fischer-Valuck BW, Kashani R, Parikh P, Yang D, Zhao T, et al. Online magnetic resonance image guided adaptive radiation therapy: first clinical ppplications. Int J Radiat Oncol Biol Phys. 2016;94(2):394\u2013403.","DOI":"10.1016\/j.ijrobp.2015.10.015"},{"key":"1813_CR13","doi-asserted-by":"crossref","unstructured":"Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018;126(3):519\u201326.","DOI":"10.1016\/j.radonc.2017.11.032"},{"key":"1813_CR14","doi-asserted-by":"crossref","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"1813_CR15","doi-asserted-by":"crossref","unstructured":"van Timmeren JE, Chamberlain M, Krayenbuehl J, Wilke L, Ehrbar S, Bogowicz M, et al. Treatment plan quality during online adaptive re-planning. Radiat Oncol. 2020;15(1):203.","DOI":"10.1186\/s13014-020-01641-0"},{"key":"1813_CR16","doi-asserted-by":"crossref","unstructured":"Finazzi T, Palacios MA, Spoelstra FOB, Haasbeek CJA, Bruynzeel AME, Slotman BJ, et al. Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors. Int J Radiat Oncol Biol Phys. 2019;104(4):933\u201341.","DOI":"10.1016\/j.ijrobp.2019.03.035"},{"key":"1813_CR17","doi-asserted-by":"crossref","unstructured":"Henke LE, Kashani R, Hilliard J, DeWees TA, Curcuru A, Przybysz D, et al. In Silico Trial of MR-Guided Midtreatment Adaptive Planning for Hypofractionated Stereotactic Radiation Therapy in Centrally Located Thoracic Tumors. Int J Radiat Oncol Biol Phys. 2018;102(4):987\u201395.","DOI":"10.1016\/j.ijrobp.2018.06.022"},{"key":"1813_CR18","doi-asserted-by":"crossref","unstructured":"Palacios MA, Bohoudi O, Bruynzeel AME, van S\u00f6rsen de Koste JR, Cobussen P, Slotman BJ, et al. Role of daily plan adaptation in MR-guided stereotactic ablative radiation therapy for adrenal metastases. Int J Radiat Oncol Biol Phys. 2018;102(2):426\u201333.","DOI":"10.1016\/j.ijrobp.2018.06.002"},{"issue":"3","key":"1813_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.brachy.2014.01.004","volume":"13","author":"J Mayadev","year":"2014","unstructured":"Mayadev J, Qi L, Lentz S, Benedict S, Courquin J, Dieterich S, et al. Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2014;13(3):233\u20139.","journal-title":"Brachytherapy"},{"issue":"5","key":"1813_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/10929080701684754","volume":"12","author":"WT Brown","year":"2007","unstructured":"Brown WT, Wu X, Wen B-C, Fowler JF, Fayad F, Amendola BE, et al. Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors. Comput Aided Surg. 2007;12(5):253\u201361.","journal-title":"Comput Aided Surg"},{"key":"1813_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fonc.2016.00215","volume":"6","author":"LGW Kerkmeijer","year":"2016","unstructured":"Kerkmeijer LGW, Fuller CD, Verkooijen HM, Verheij M, Choudhury A, Harrington KJ, et al. The MRI-linear accelerator consortium: evidence-based clinical introduction of an innovation in radiation oncology connecting researchers, methodology, data collection, quality assurance, and technical development. Front Oncol. 2016;6:215.","journal-title":"Front Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01813-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01813-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T13:06:13Z","timestamp":1620133573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01813-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01813-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional guidelines were followed.  Informed consent was obtained from all patients. All patients gave their consent for retrospective data analysis.  The study was approved by the cantonal ethics committee Zurich (BASEC-Nr. 2018-01794).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.  Nicolaus Andratschke has received honoraria for advisory board participation and\/or speaker fees from AstraZeneca, Debiopharm, Viewray, Brainlab and research grants from Brainlab.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}